RayzeBio, Inc. Common Stock
RayzeBio, Inc. Common Stock（RYZB）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · RYZB · 截至 2023年12月31日
股东结构概览
108
机构持有人数
▲ 40 vs Q3
$3.40B
机构持仓总市值
▲ $2.20B vs Q3
60.02M
总流通股
freeFloat 58.02%
54.76M
13F 申报持股数
▲ 577,554 vs Q3
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
RYZB 最大股东 · 机构持仓
Q4 2023 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
VIKING GLOBAL INVESTORS LP pharmaceutical preparations | 6.64M | 43.13% | 43.13% | $412.98B | Feb 14, 2024 | — held |
VENBIO PARTNERS LLC pharmaceutical preparations | 5.16M | 33.49% | 33.49% | $320.68B | Feb 14, 2024 | — held |
VERSANT VENTURE MANAGEMENT, LLC pharmaceutical preparations | 5.16M | 33.49% | 33.49% | $320.68B | Feb 8, 2024 | — held |
VR ADVISER, LLC pharmaceutical preparations | 4.03M | 26.17% | 26.17% | $250.57B | Feb 14, 2024 | ▲ 13.6K |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 3.50M | 22.76% | 22.76% | $215.91B | Feb 12, 2024 | ▼ 371.8K |
SOFINNOVA INVESTMENTS, INC. pharmaceutical preparations | 2.42M | 15.71% | 15.71% | $150.42B | Aug 15, 2024 | — held |
ORBIMED ADVISORS LLC pharmaceutical preparations | 2.37M | 15.36% | 15.36% | $147.05B | Feb 14, 2024 | ▼ 257.7K |
REDMILE GROUP, LLC pharmaceutical preparations | 1.86M | 12.06% | 12.06% | $115.49B | Feb 14, 2024 | — held |
SAMSARA BIOCAPITAL, LLC pharmaceutical preparations | 1.85M | 11.99% | 11.99% | $114.76B | Feb 14, 2024 | — held |
BLACKROCK INC. pharmaceutical preparations | 1.37M | 8.89% | 8.89% | $85.10B | Feb 13, 2024 | ▲ 1.36M |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q4 2023 对比上季度
Q4 2023
15
增持
+4.07M 股14
新建仓
首次建仓12
减持
−4.88M 股0
清仓
完全退出净股数变化（前50家）
806.4K
+4.07M / −4.88M
净新增持仓人
+17
新建 14 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
RYZB 内幕交易记录
数据来源：SEC Form 4
0
买入笔数
1
卖出笔数
0.00
买卖比
$2M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
VIKING GLOBAL INVESTORS LP 10 percent owner | Feb 26, 2024 | J-Other | 1,743,556 | $62.50 | $108.97M | 0 | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Sep 19, 2023 | C-Conversion | 498,510 | — | — | 1.86M | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Sep 19, 2023 | C-Conversion | 494,687 | — | — | 1.36M | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Sep 19, 2023 | C-Conversion | 864,509 | — | — | 864.5K | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Sep 19, 2023 | C-Conversion | 432,254 | — | — | 0 | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Sep 19, 2023 | C-Conversion | 498,510 | — | — | 0 | Form 4 ↗ |
Redmile Group, LLC 10 percent owner | Sep 19, 2023 | C-Conversion | 864,509 | — | — | 0 | Form 4 ↗ |
venBio Global Strategic Fund III, L.P. 10 percent owner | Sep 19, 2023 | C-Conversion | 247,343 | — | — | 5.16M | Form 4 ↗ |
venBio Global Strategic Fund III, L.P. 10 percent owner | Sep 19, 2023 | C-Conversion | 1,123,862 | — | — | 4.91M | Form 4 ↗ |
venBio Global Strategic Fund III, L.P. 10 percent owner | Sep 19, 2023 | C-Conversion | 3,786,957 | — | — | 3.79M | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
RayzeBio, Inc. Common Stock（RYZB）主要由机构投资者持有，机构持股比例约为 91.2%。公司内部人员持股约 41.98%，散户及公众持股约占剩余的 0.00%。
RayzeBio, Inc. Common Stock 最大机构股东为 VIKING GLOBAL INVESTORS LP，截至 December 31, 2023 持有约 6.64 million 股，占总流通股的 43.13%。
目前共有 108 家机构持有 RYZB 股票，合计持仓市值约 $3.40 billion，数据来源为最新 SEC 13F 申报。
常见问题
RYZB ownershipRayzeBio, Inc. Common Stock（RYZB）主要由机构投资者持有，机构持股约 91.2%。最大股东为 VIKING GLOBAL INVESTORS LP，持股比例 43.13%。内部人员持股约 41.98%。数据来源 SEC Form 13F，截至 December 31, 2023。